- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02715375
Investigate the Effect of the CREON2000A on Asthma Control in Children With Mild to Moderate Persistent Asthma (CREON2000A)
October 30, 2020 updated by: General Innovations and Goods, Inc.
A Double Blind, Randomized, Sham Controlled Trial to Investigate the Effect of the CREON2000A on Asthma Control in Children With Mild to Moderate Persistent Asthma
This is a pivotal, 12-month, randomized, sham controlled, parallel group, multicenter, double blind study with an allocation ratio of 1:1.
The study population is children between the ages 6 to 17 years, with mild to moderate persistent asthma.
The purpose of the study is to determine whether the CREON2000A, an environmental control device, will decrease asthma severity, as measured by the Composite Asthma Severity Index (CASI), in children with mild to moderate persistent allergic asthma over a twelve month period.
Study Overview
Detailed Description
The pilot study (Protocol #PA-01-052; Health Effects of CREON2000 in Asthmatic Children.
IB ID# GI 1001) offered preliminary evidence that the CREON2000A system may be beneficial in asthma.
This study is a follow-up, using children, aged 6 to 17 with mild to moderate persistent asthma, as the subjects of the study.
Children are usually treated with fewer controller medications and have fewer confounding co-morbidities making it more likely to detect a therapeutic benefit from an environmental intervention.
The study will involve 4 study site visits, 2 home visits, and 7 phone calls.
Adjustment of asthma therapy by the site clinician will occur at baseline (Visit 1) and at each follow-up office visit after Visit 1 using a modified algorithm based on the National Asthma Education and Prevention Program Expert Panel Report 3 (NAEPP EPR3) guidelines.
Enrollment will be over 18 months.
The study duration for each subject will be 12 months.
Study Type
Interventional
Enrollment (Actual)
83
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Florida
-
Homestead, Florida, United States, 33030
- Advanced Research Institute of Miami, LLC
-
-
Kentucky
-
Lexington, Kentucky, United States, 40509
- Allergy & Asthma Associates
-
-
Ohio
-
Cincinnati, Ohio, United States, 45229
- Cincinnati Childrens Hospital Medical Center
-
Cincinnati, Ohio, United States, 45231
- Bernstein Clinical Research Center, LLC
-
Columbus, Ohio, United States, 43205
- Columbus Nationwide Children's Hospital
-
Dayton, Ohio, United States, 45414
- Ohio Pediatric Research Assn.
-
Toledo, Ohio, United States, 43560
- Toledo Institute of Clinical Research
-
Willoughby, Ohio, United States, 44094
- Great Lakes Medical Research, LLC
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
6 years to 18 years (Child, Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion criteria
- Males and Females ages 6.0 to 17.0 years.
- Subjects with a physician diagnosis of mild or moderate persistent asthma.
- FEV1 ≥ 60% predicted with ≥ 12% improvement after bronchodilator therapy.
- Must have evidence of; 1) serum specific IgE (immunocap) ≥ .35 or 2) a positive skin prick test to one or more common indoor allergens including standardized house dust mite, cat, dog, cockroach, mouse in the past.
Exclusion criteria
- Current smokers
- Passive exposure to environmental tobacco smoke at home or active fireplaces and other sources of air particulates (wood burning stoves, kerosene heaters) at home.
- Diagnosed by a physician with a chronic lung disease other than asthma.
- Upper or lower respiratory infection within four weeks prior to enrollment.
- Known to have any other chronic illness (besides asthma) that is not well controlled at the time of screening (Visit 1).
- History of a life threatening asthma attack requiring cardiopulmonary support, intubation with ventilatory support, hospitalization in an intensive care unit or hospitalization for asthma within 6 months preceding study screening (Visit 1).
- Participation in another investigational drug/device study within the past 3 months (not including chart or observational studies)
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Device: CREON2000A
Children with mild to moderate asthma maintains allergy medicines have an experimental ultra violet device installed in their homes.
|
|
Sham Comparator: Device: Sham Comparator
Children with mild to moderate asthma maintains allergy medicines have a sham device using a shielded blue light sham lamp that otherwise resembles the experimental device installed in their homes.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in CASI Score
Time Frame: Baseline and 12 months
|
Difference between study arms in the change in asthma severity as measured by the Composite Asthma Severity Index (CASI) from Baseline (Visit 1) to the 12-month follow up office visit
|
Baseline and 12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Forced Expiratory Volume (FEV1)
Time Frame: Baseline and 12 months
|
• in the mean change in FEV1 (% predicted) from Baseline (Visit 1) to 12-month follow up office visit
|
Baseline and 12 months
|
Mean change in number of day time symptom scores
Time Frame: Baseline, 4, 8 and12 months
|
• in the mean change in number of day time symptom scores from Baseline (Visit 1) to the 4, 8 and 12-month follow up office visits
|
Baseline, 4, 8 and12 months
|
Mean change in number of night time symptoms
Time Frame: Baseline, 4, 8 and 12 months
|
• in the mean change in number of night time symptom scores from Baseline (Visit 1) to the 4, 8 and 12-month follow up office visits
|
Baseline, 4, 8 and 12 months
|
Mean change in the number of daily puffs/inhalations of short-acting beta-agonist (SABA) rescue medication
Time Frame: Baseline, 4, 8 and 12 months
|
• in the mean change in the number of daily puffs/inhalations of short-acting beta-agonist rescue medication taken over 14 days prior to each evaluation, from Baseline (Visit 1) to 4, 8 and 12 month follow up office visits
|
Baseline, 4, 8 and 12 months
|
Mean Change in CASI
Time Frame: Baseline, 4, 8 and 12 months
|
• in the mean change in CASI from Baseline (Visit 1) to 4- and 8- and 12-month follow up office visits
|
Baseline, 4, 8 and 12 months
|
Mean change in daily does of inhaled glucocorticoids taken (µg/day)
Time Frame: Baseline 4, 8 and 12 months
|
• in the mean change in daily dose of inhaled glucocorticoids taken (µg/day) by participants from Baseline (Visit 1) to 4, 8 and 12 months follow up office visits.
|
Baseline 4, 8 and 12 months
|
Mean change in the percentage of patients with an asthma exacerbation
Time Frame: Baseline and12 months
|
• in the mean change in the percentage of patients with an asthma exacerbation during the period from baseline (Visit 1) to the 12 month follow up office visit
|
Baseline and12 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Investigators
- Study Chair: Jonathan Bernstein, MD, University of Cincinnati, Cincinnati, Ohio
- Principal Investigator: Mark Glazman, PhD, General Innovations and Goods, Inc. (GI&G)
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
March 10, 2016
Primary Completion (Actual)
October 15, 2020
Study Completion (Actual)
October 15, 2020
Study Registration Dates
First Submitted
March 10, 2016
First Submitted That Met QC Criteria
March 16, 2016
First Posted (Estimate)
March 22, 2016
Study Record Updates
Last Update Posted (Actual)
November 3, 2020
Last Update Submitted That Met QC Criteria
October 30, 2020
Last Verified
October 1, 2020
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- U44-CRE-01
- U44AI074918 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Asthma
-
Vanderbilt University Medical CenterNot yet recruitingAsthma in Children | Asthma Attack | Asthma Acute | Acute Asthma Exacerbation | Asthma; StatusUnited States
-
University of California, San FranciscoCompletedAsthma in Children | Asthma Attack | Asthma Acute | Asthma ChronicUnited States
-
Johann Wolfgang Goethe University HospitalCompleted
-
SingHealth PolyclinicsNot yet recruitingAsthma | Asthma in Children | Asthma Attack | Asthma Acute | Asthma Chronic
-
Universita di VeronaCompleted
-
Parc de Salut MarActive, not recruitingAsthma in Children | Persistent Asthma | Asthma ExacerbationSpain
-
Forest LaboratoriesCompleted
-
Brunel UniversityKarolinska InstitutetUnknown
-
Johann Wolfgang Goethe University HospitalCompletedExercise-induced AsthmaGermany